Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call

  
    
  
  
    
      Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast:
    
    
      What: Aastrom Biosciences, Inc. First Quarter Fiscal Year 2007 Investor 
      Conference Call
    
    
      When: Thursday, November 9, 2006 @ 11:00 am (EST)
    
    
      Where: http://www.vcall.com/IC/CEPage.asp?ID=109389
    
    
      How: • For live Internet access, simply 
      log on to the web at the address above.
    
    
      • For phone access, interested parties 
      should call toll-free [phone] before the start of the call to 
      register and identify themselves as registrants of the “Aastrom 
      Conference Call”. Any registered caller on the 
      toll-free line may ask for call operator for directions to be placed in 
      the queue for the Question & Answer session. If calling from outside the 
      U.S., please use the international phone number [phone].
    
    
      • To download the podcast, simply log 
      on to the web at the address above.
    
    
      Contact: Kris Maly, Investor Relations Department, [phone] or [e-mail]
    
    
      If you are unable to participate during the live call, the webcast will 
      be available for replay at http://www.investorcalendar.com/ 
      for 60 days. Also, through November 19, 2006, the audio replay of the 
      call will be available by dialing toll-free [phone], or from 
      outside the U.S. [phone]. When prompted, the Account # is: 286, 
      and the Conference ID# is: 215272.
    
    
      Aastrom Biosciences, Inc. (NASDAQ: ASTM) is developing autologous cell 
      products for the repair or regeneration of multiple human tissues, based 
      on its proprietary Tissue Repair Cell (TRC) technology. Aastrom's 
      TRC-based products are a unique cell mixture containing stromal, stem 
      and progenitor cell populations, produced outside the body from a small 
      amount of bone marrow taken from the patient. TRC-based products have 
      been used in over 230 patients, and are currently in clinical trials for 
      bone regeneration (long bone fractures and spine fusion) and vascular 
      regeneration (critical limb ischemia) applications. The Company has 
      reported positive interim clinical trial results for TRCs suggesting 
      both the clinical safety and the ability of TRCs to induce tissue 
      regeneration in long bone fractures and jaw bone reconstruction. 
      Recently, the Company's proprietary TRCs received an Orphan Drug 
      Designation from the U.S. Food and Drug Administration for use in the 
      treatment of osteonecrosis of the femoral head. In addition, Aastrom is 
      developing plans for a TRC-based therapy for cardiac regeneration.
    
    
      For more information, visit Aastrom’s website 
      at www.aastrom.com.
    
  
Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following
Webcast:

   What: Aastrom Biosciences, Inc. First Quarter Fiscal Year 2007
Investor Conference Call

   When: Thursday, November 9, 2006 @ 11:00 am (EST)

   Where: http://www.vcall.com/IC/CEPage.asp?ID=109389

   How: -- For live Internet access, simply log on to the web at the
address above.

       -- For phone access, interested parties should call toll-free
        [phone] before the start of the call to register and
        identify themselves as registrants of the "Aastrom Conference
        Call". Any registered caller on the toll-free line may ask for
        call operator for directions to be placed in the queue for the
        Question & Answer session. If calling from outside the U.S.,
        please use the international phone number [phone].

       -- To download the podcast, simply log on to the web at the
        address above.

   Contact: Kris Maly, Investor Relations Department, [phone]
or [e-mail]

   If you are unable to participate during the live call, the webcast
will be available for replay at http://www.investorcalendar.com/ for
60 days. Also, through November 19, 2006, the audio replay of the
call will be available by dialing toll-free [phone], or from
outside the U.S. [phone]. When prompted, the Account # is: 286,
and the Conference ID# is: 215272.

   Aastrom Biosciences, Inc. (NASDAQ: ASTM) is developing autologous
cell products for the repair or regeneration of multiple human
tissues, based on its proprietary Tissue Repair Cell (TRC) technology.
Aastrom's TRC-based products are a unique cell mixture containing
stromal, stem and progenitor cell populations, produced outside the
body from a small amount of bone marrow taken from the patient.
TRC-based products have been used in over 230 patients, and are
currently in clinical trials for bone regeneration (long bone
fractures and spine fusion) and vascular regeneration (critical limb
ischemia) applications. The Company has reported positive interim
clinical trial results for TRCs suggesting both the clinical safety
and the ability of TRCs to induce tissue regeneration in long bone
fractures and jaw bone reconstruction. Recently, the Company's
proprietary TRCs received an Orphan Drug Designation from the U.S.
Food and Drug Administration for use in the treatment of osteonecrosis
of the femoral head. In addition, Aastrom is developing plans for a
TRC-based therapy for cardiac regeneration.

   For more information, visit Aastrom's website at www.aastrom.com.